» Articles » PMID: 38561395

Amyloid-β Prediction Machine Learning Model Using Source-based Morphometry Across Neurocognitive Disorders

Abstract

Previous studies have developed and explored magnetic resonance imaging (MRI)-based machine learning models for predicting Alzheimer's disease (AD). However, limited research has focused on models incorporating diverse patient populations. This study aimed to build a clinically useful prediction model for amyloid-beta (Aβ) deposition using source-based morphometry, using a data-driven algorithm based on independent component analyses. Additionally, we assessed how the predictive accuracies varied with the feature combinations. Data from 118 participants clinically diagnosed with various conditions such as AD, mild cognitive impairment, frontotemporal lobar degeneration, corticobasal syndrome, progressive supranuclear palsy, and psychiatric disorders, as well as healthy controls were used for the development of the model. We used structural MR images, cognitive test results, and apolipoprotein E status for feature selection. Three-dimensional T1-weighted images were preprocessed into voxel-based gray matter images and then subjected to source-based morphometry. We used a support vector machine as a classifier. We applied SHapley Additive exPlanations, a game-theoretical approach, to ensure model accountability. The final model that was based on MR-images, cognitive test results, and apolipoprotein E status yielded 89.8% accuracy and a receiver operating characteristic curve of 0.888. The model based on MR-images alone showed 84.7% accuracy. Aβ-positivity was correctly detected in non-AD patients. One of the seven independent components derived from source-based morphometry was considered to represent an AD-related gray matter volume pattern and showed the strongest impact on the model output. Aβ-positivity across neurological and psychiatric disorders was predicted with moderate-to-high accuracy and was associated with a probable AD-related gray matter volume pattern. An MRI-based data-driven machine learning approach can be beneficial as a diagnostic aid.

Citing Articles

Alzheimer's disease neuropathology and its estimation with fluid and imaging biomarkers.

Thal D, Poesen K, Vandenberghe R, De Meyer S Mol Neurodegener. 2025; 20(1):33.

PMID: 40087672 DOI: 10.1186/s13024-025-00819-y.


Machine learning models for dementia screening to classify brain amyloid positivity on positron emission tomography using blood markers and demographic characteristics: a retrospective observational study.

Kimura N, Sasaki K, Masuda T, Ataka T, Matsumoto M, Kitamura M Alzheimers Res Ther. 2025; 17(1):25.

PMID: 39838434 PMC: 11748352. DOI: 10.1186/s13195-024-01650-1.


Development and Validation of the Communities Geriatric Mild Cognitive Impairment Risk Calculator (CGMCI-Risk).

Chen J, Fang Q, Yang K, Pan J, Zhou L, Xu Q Healthcare (Basel). 2024; 12(20).

PMID: 39451430 PMC: 11506964. DOI: 10.3390/healthcare12202015.

References
1.
Hardy J, Higgins G . Alzheimer's disease: the amyloid cascade hypothesis. Science. 1992; 256(5054):184-5. DOI: 10.1126/science.1566067. View

2.
Jack Jr C, Bennett D, Blennow K, Carrillo M, Dunn B, Budd Haeberlein S . NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018; 14(4):535-562. PMC: 5958625. DOI: 10.1016/j.jalz.2018.02.018. View

3.
Beach T, Monsell S, Phillips L, Kukull W . Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J Neuropathol Exp Neurol. 2012; 71(4):266-73. PMC: 3331862. DOI: 10.1097/NEN.0b013e31824b211b. View

4.
Matsui Y, Tanizaki Y, Arima H, Yonemoto K, Doi Y, Ninomiya T . Incidence and survival of dementia in a general population of Japanese elderly: the Hisayama study. J Neurol Neurosurg Psychiatry. 2008; 80(4):366-70. DOI: 10.1136/jnnp.2008.155481. View

5.
Hampel H, Cummings J, Blennow K, Gao P, Jack Jr C, Vergallo A . Developing the ATX(N) classification for use across the Alzheimer disease continuum. Nat Rev Neurol. 2021; 17(9):580-589. DOI: 10.1038/s41582-021-00520-w. View